Latest

Ozempic

·September 4, 2024·5 min read

No Link Found Between Ozempic and Suicide Risk

A new study has found no evidence that GLP-1 analogues, common diabetes drugs, increase the risk of suicide, self-harm, or related mental health issues. Researchers analyzed data from around 300,000 people treated with these medications and found no clear link between the drugs and mental health risks.

Featured Genetics Neuroscience

·July 15, 2024·5 min read

Adjusting Proteins Increases Ozempic’s Effectiveness

Adjusting melanocortin proteins in the brain enhances the effectiveness of GLP-1 diabetes and weight-loss drugs. By inhibiting MC3R or activating MC4R, mice showed increased sensitivity to these drugs, leading to more significant weight loss and reduced feeding without additional side effects.

Featured Neurology Neuroscience

·July 12, 2024·5 min read

Ozempic Reduces Dementia Risk, Curbs Nicotine Cravings

A new study finds that semaglutide, known as Ozempic/Wegovy, does not negatively impact brain health and may reduce cognitive problems and nicotine dependence. The analysis, using over 100 million patient records, revealed no increased risk of neurological or psychiatric conditions compared to other antidiabetic medications. These findings suggest semaglutide's benefits may extend beyond diabetes management. Further research is needed to confirm these potential benefits.

Featured Neuroscience Visual Neuroscience

·July 3, 2024·7 min read

Ozempic Linked to Increased Risk of Blinding Eye Condition

A new study reveals that patients prescribed semaglutide (Ozempic or Wegovy) for diabetes or weight loss have a higher risk of developing NAION, a potentially blinding eye condition. Diabetic patients on semaglutide were over four times more likely to be diagnosed with NAION, while overweight patients were over seven times more likely. The findings suggest the need for careful discussions between patients and doctors about this risk. NAION remains a rare but serious condition with no effective treatments.

This shows an older man and a brain scan.

Featured Neurology Neuroscience

·June 21, 2024·4 min read

Ozempic May Reduce Alzheimer’s Risk

GLP-1 agonists like Ozempic reduce the risk of dementia in type 2 diabetes patients. The research followed over 88,000 individuals for up to ten years, showing a 30% lower risk compared to sulfonylureas and a 23% lower risk compared to DPP-4 inhibitors. These findings can guide doctors in selecting medications for older diabetes patients. However, further randomized trials are needed to confirm these results.

Featured Neuroscience Psychology

·June 3, 2024·3 min read

Ozempic May Reduce Alcohol Abuse Risk

Diabetes drugs Wegovy and Ozempic, containing semaglutide, significantly reduce the incidence and recurrence of alcohol-use disorder (AUD). Analyzing health records, researchers observed a 50% to 56% decrease in AUD among patients treated with semaglutide.

This shows a sad man and a whiskey bottle.

Featured Neuroscience Psychology

·June 8, 2023·5 min read

Ozempic Shows Potential as Treatment for Alcohol Dependence

Semaglutide, or Ozempic, a medication used for type 2 diabetes and obesity, may also be effective in treating alcohol dependence. The drug reduced alcohol relapse drinking and overall alcohol intake in rats by more than half.